TrialClinical cancer research : an official journal of the American Association for Cancer Research2008

Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.

Gustavo Ayala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.